BioSpace News Archive

Medivir AB announced promising interim safety and efficacy data from its ongoing phase 1b/2a study of first-in-class candidate drug fostrox in combination with Lenvima® in advanced hepatocellular carcinoma patients for whom current first- or second-line treatment has proven ineffective or is not tolerable.

ANGLE plc, a world-leading liquid biopsy company with innovative circulating tumor cell diagnostic solutions for the research and diagnostic oncology market, is pleased to announce the launch of its Portrait™ Flex CTC assay*.

Celyad Oncology, announces its financial results and recent business developments for the first half year, ended June 30, 2023.

Ascletis Pharma Inc. announces that it will participate in the upcoming Morgan Stanley 21st Annual Global Healthcare Conference.

The International Centers for Precision Oncology Foundation and NTP Radioisotopes SOC Ltd. announced a collaboration to promote international education standards in Radiomolecular Precision Oncology and support the establishment and expansion of a global network of Theranostics Centers.

Oncorena announces first patient treated in the Phase I/II trial of the first-in-class compound, ONC175, in patients with metastatic renal cancer and dialysis.

Xenon Pharmaceuticals Inc., a neurology-focused biopharmaceutical company, announced a summary of its oral and poster presentations at the 35th International Epilepsy Congress taking place in Dublin, Ireland from September 2-6, 2023.

Genmab A/S and Seagen Inc. announced that the Phase 3 innovaTV 301 global trial in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy who received TIVDAK®, compared with chemotherapy alone, met its primary endpoint of overall survival.

The Global HPV Consortium, a worldwide public and private collaboration focused on accelerating prevention of Human Papillomavirus and eliminating cervical cancer, launched in Kuala Lumpur, Malaysia.

Novozymes and the Danish industrial biotech company, Bactolife, have signed a joint development and commercialization agreement to finish development and launch the biosolution Ablacto+.